Pds biotech to host key opinion leader event to discuss positive, updated data from phase 2 versatile-002 clinical trial with versamune® hpv in combination with keytruda® in recurrent or metastatic head and neck cancer

Company to host key opinion leader event on may 8 at 1:30pm et to discuss updated results of versatile-002, unmet treatment needs in advanced head and neck cancer and planned triple combination trial
PDSB Ratings Summary
PDSB Quant Ranking